A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Milvexian
- drug: Apixaban
- drug: Placebo
- drug: Apixaban Placebo
Eligibility
Inclusion Criteria:
- Minimum age of 18 years
- Medically stable and appropriate for chronic antithrombotic treatment
- Atrial fibrillation eligible to receive anticoagulation
- Participant must satisfy one or both of the following categories of risk factors (a or
b): a) one or more of the following risk factors: i) age greater than or equal to 75
years, ii) history of any type of stroke including symptomatic stroke of any kind. b)
two or more of the following risk factors: i) age between 65 and 74 years, ii)
hypertension, iii) diabetes mellitus, iv) atherosclerotic vascular disease, v) heart
failure
Exclusion Criteria:
- Hemodynamically significant valve disease or those with valve disease that will
potentially require surgical valve replacement during the study
- Any condition other than AF that requires chronic anticoagulation
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.